Circovirus sequences associated with piglet weight loss disease (PWD)
The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccine, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided.
1. A virus-like particle (VLP) generated from a vector comprising a nucleic acid having at least 90% identity to SEQ ID NO:25.
2. The VLP of claim 1 , wherein said nucleic acid has at least 95% identity to SEQ ID NO:25.
3. The VLP of claim 1 , wherein the vector is a baculovirus vector.
4. A vaccine composition comprising the VLP of claim 1 and a pharmaceutically or veterinarily acceptable carrier.
5. An immunogenic composition, comprising the VLP of claim 1 and a pharmaceutically or veterinarily acceptable carrier.
6. A method of inducing an immune response against porcine circovirus type B (PCVB), said method comprising administering to a mammalian subject a therapeutically effective amount of a vaccine composition according to claim 4 .
7. The method of claim 6 , wherein the mammalian subject is a pig.
8. A virus-like particle (VLP) generated from a vector capable of expressing at least one polypeptide comprising an amino acid sequence having at least 90% identity to SEQ ID NO:26.
9. The VLP of claim 8 , wherein said amino acid sequence has at least 95% identity to SEQ ID NO:26.
10. The VLP of claim 8 , wherein the vector is a baculovirus vector.
11. A vaccine composition comprising the VLP of claim 8 and a pharmaceutically or veterinarily acceptable carrier.
12. An immunogenic composition, comprising the VLP of claim 8 and a pharmaceutically or veterinarily acceptable carrier.
13. A method of inducing an immune response against porcine circovirus type B (PCVB), said method comprising administering to a mammalian subject a therapeutically effective amount of a vaccine composition according to claim 11 .
14. The method of claim 13 , wherein the mammalian subject is a pig.